Defunct Company
Total Trials
5
As Lead Sponsor
As Collaborator
0
Total Enrollment
327
NCT00886353
Safety and Tolerability Study of APN01 (Recombinant Human Angiotensin Converting Enzyme 2)
Phase: Phase 1
Role: Lead Sponsor
Start: Apr 30, 2009
Completion: Dec 31, 2009
NCT01245400
Safety and Efficacy Study of the Z-Lig Medical Device Compared to Allograft
Phase: N/A
Start: Nov 30, 2010
Completion: Apr 30, 2017
NCT01513278
Study of APN201 (Liposomal Recombinant Human Cu/Zn-Superoxide Dismutase) for the Prevention of Radiation-induced Dermatitis in Women With Breast Cancer
Phase: Phase 1/2
Start: Jan 31, 2012
Completion: May 31, 2012
NCT04335136
Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19
Phase: Phase 2
Start: Apr 30, 2020
Completion: Dec 26, 2020
NCT05065645
Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled APN01 Developed as Treatment for COVID-19
Start: Oct 19, 2021
Completion: May 27, 2022